Wesnes et al., 2009 4646. Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 2009; 8: 615-626, doi: 10.1517/14740330903260790. https://doi.org/10.1517/1474033090326079...
|
Randomized, double-blind, placebo-controlled study |
12 patients |
Over 65 years of age |
10 mg SOL, 10 mg OXY and PLA |
3 crossover periods of single dose treatment separated by two 14-day washout periods |
No evidence of cognitive impairment with the use of 10 mg solifenacin compared to the placebo group. Oxybutynin was associated with impaired cognitive functions (impaired attention and continued attention power, working memory and alert self-assessment) |
Wagg et al., 2013 3030. Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: The SENIOR study. Eur Urol 2013; 64: 74-81, doi: 10.1016/j.eururo.2013.01.002. https://doi.org/10.1016/j.eururo.2013.01...
|
Randomized, double-blind, triple-crossover trial |
26 patients |
Patients over 75 years of age and with mild cognitive impairment |
SOL 5 mg once daily, OXY 5 mg twice daily, or PLA |
3 treatment periods of 21 days each, separated by 21-day washout periods |
Solifenacin had no detectable effect on cognition while oxybutynin was associated with a statistically significant decrease in both power and continuity of attention |
Kosilov et al., 2018 3232. Kosilov K, Kuzina I, Kuznetsov V, Gainullina Y, Kosilova L, Prokofyeva A, et al. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Aging Male 2018; 21: 121-129, doi: 10.1080/13685538.2017.1398723. https://doi.org/10.1080/13685538.2017.13...
|
Randomized study 3 groups |
262 patients |
Male patients aged 52-79 years, diagnosed with BPH and OAB, with at least 24 points on the MMSEs |
Same dosage of TAM (0.4 mg) and different dosages of SOL (10 and 20 mg) and PLA were applied: SOL 10 mg +TAM or SOL 20 mg + TAM or PLA + TAM |
8 weeks |
No statistically significant variation in relation to cognitive changes |
Kosilov et al., 2018 4545. Kosilov K, Kuzina I, Loparev S, Gainullina Y, Kosilova L, Prokofyeva A. Influence of the short-term intake of high doses of solifenacin and trospium on cognitive function and health-related quality of life in older women with urinary incontinence. Int Neurourol J 2018; 22: 41-50, doi: 10.5213/inj.1834996.498. https://doi.org/10.5213/inj.1834996.498...
|
Randomized study 3 groups |
312 patients |
Women, aged 60-83 years, with urge urinary incontinence or mixed urinary incontinence, with at least 24 points on MMSEs |
SOL 20 mg/d and TRO 60 mg/d, SOL 10 mg/d and TRO 30 mg/d or placebo: SOL 20 mg/d or TRO 30 mg/d or PLA SOL 10 mg/d or TRO 30 mg/d or PLA |
8 weeks |
No increase in cognitive impairment risk |
Park, 2013 4848. Park JW. The effect of solifenacin on cognitive function following stroke. dementia and geriatric cognitive disorders extra. Dement Geriatr Cogn Dis Extra 2013; 3: 143-147, doi: 10.1159/000350029. https://doi.org/10.1159/000350029...
|
Retrospective case-control study |
66 patients with stroke 66 controls |
Stroke patients presenting urinary urgency and frequency symptoms |
SOL 5 or 10 mg/d or PLA |
2 months of solifenacin use |
Solifenacin treatment did not affect short-term cognitive performance (evaluated with MMSEs or CDR-SB) in stroke patients |
Triantafylidis et al., 2018 5757. Triantafylidis LK, Clemons JS, Peron EP, Roefaro J, Zimmerman KM. Brain over bladder: a systematic review of dual cholinesterase inhibitor and urinary anticholinergic use. Drugs Aging 2018; 35: 27-41, doi: 10.1007/s40266-017-0510-6. https://doi.org/10.1007/s40266-017-0510-...
|
Systematic review |
4 studies |
Dual use of cholinesterase inhibitors and urinary anticholinergics in older adults |
Concomitant use of cholinesterase inhibitors and urinary anticholinergics |
NA |
Inconclusive: no changes in cognition in 3 studies evaluated. Only one study showing an improvement in cognition with high doses of donepezil and solifenacin |
Hampel et al., 2017 4747. Hampel C, Betz D, Burger M, Nowak C, Vogel M. Solifenacin in the elderly: results of an observational study measuring efficacy, tolerability and cognitive effects. Urol Int 2017; 98: 350-357, doi: 10.1159/000455257. https://doi.org/10.1159/000455257...
|
Observational study |
774 patients |
Patients aged ≥70 years with OAB |
SOL 5 or 10 mg/d |
12 weeks |
No relevant effect of solifenacin on cognitive function in the MMSEs was observed in this elderly population |